Nasogastric omeprazole: effects on gastric pH in critically Ill patients. 1997

D H Balaban, and C W Duckworth, and D A Peura
Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, USA.

OBJECTIVE The efficacy of omeprazole administered by the nasogastric route has not been adequately studied. We sought to determine whether nasogastrically administered omeprazole could effectively maintain an intragastric pH greater than 4.0 in patients hospitalized in a medical intensive care unit. METHODS Patients were considered eligible for the study if they had a nasogastric feeding tube in place and had not received omeprazole, antacids, or histamine-2 blockers in the 5 days preceding study enrollment. Exclusionary criteria included active GI bleeding or a mean baseline gastric pH greater than 4.0. Patients served as their own controls during a 24-h lead-in period, during which baseline intragastric pH was measured by gastric aspirate. Omeprazole, 20 or 40 mg, was administered once daily with water through a nasogastric tube. Intragastric pH was measured every 4-8 h for a maximum of 3 days following drug administration. RESULTS Twenty patients were considered eligible for the study; 10 were excluded because of an elevated baseline gastric pH (n = 8) or because proper gastric aspirates could not be obtained (n = 2). The mean baseline intragastric pH in four patients receiving omeprazole 20 mg q.d. was 2.4 +/- 1.1 and increased to 3.7 +/- 1.6 after drug administration (p = 0.013). The mean baseline intragastric pH in six patients receiving omeprazole 40 mg q.d. was 2.8 +/- 0.8 and increased to 5.7 +/- 1.1 after drug administration (p < 0.001). The percentage of intragastric pH values greater than 4.0 after drug administration was 34.2% in patients receiving omeprazole 20 mg q.d. and 84.7% in those receiving omeprazole 40 mg q.d. CONCLUSIONS Nasogastric omeprazole 40 mg q.d. is effective in maintaining an intragastric pH greater than 4.0 in critically ill patients. The nasogastric administration of omeprazole offers a cost-effective therapeutic option for acid suppression in patients at risk for stress mucosal ulceration.

UI MeSH Term Description Entries
D007441 Intubation, Gastrointestinal The insertion of a tube into the stomach, intestines, or other portion of the gastrointestinal tract to allow for the passage of food products, etc. Intubation, Nasogastric,Gastrointestinal Intubation,Gastrointestinal Intubations,Intubations, Gastrointestinal,Intubations, Nasogastric,Nasogastric Intubation,Nasogastric Intubations
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D003365 Costs and Cost Analysis Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs. Affordability,Analysis, Cost,Cost,Cost Analysis,Cost Comparison,Cost Measures,Cost-Minimization Analysis,Costs and Cost Analyses,Costs, Cost Analysis,Pricing,Affordabilities,Analyses, Cost,Analyses, Cost-Minimization,Analysis, Cost-Minimization,Comparison, Cost,Comparisons, Cost,Cost Analyses,Cost Comparisons,Cost Measure,Cost Minimization Analysis,Cost, Cost Analysis,Cost-Minimization Analyses,Costs,Measure, Cost,Measures, Cost
D003422 Critical Care Health care provided to a critically ill patient during a medical emergency or crisis. Intensive Care,Intensive Care, Surgical,Surgical Intensive Care,Care, Critical,Care, Intensive,Care, Surgical Intensive
D005260 Female Females
D005744 Gastric Acid Hydrochloric acid present in GASTRIC JUICE. Hydrochloric Acid, Gastric,Acids, Gastric,Acids, Gastric Hydrochloric,Gastric Acids,Gastric Hydrochloric Acid,Gastric Hydrochloric Acids,Hydrochloric Acids, Gastric

Related Publications

D H Balaban, and C W Duckworth, and D A Peura
February 1992, Lancet (London, England),
D H Balaban, and C W Duckworth, and D A Peura
July 2000, Critical care medicine,
D H Balaban, and C W Duckworth, and D A Peura
July 1997, Intensive care medicine,
D H Balaban, and C W Duckworth, and D A Peura
January 1998, Intensive care medicine,
D H Balaban, and C W Duckworth, and D A Peura
July 2001, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,
D H Balaban, and C W Duckworth, and D A Peura
January 2000, Alimentary pharmacology & therapeutics,
D H Balaban, and C W Duckworth, and D A Peura
January 2019, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG,
D H Balaban, and C W Duckworth, and D A Peura
December 2017, Critical care nurse,
D H Balaban, and C W Duckworth, and D A Peura
December 2010, Critical care nurse,
D H Balaban, and C W Duckworth, and D A Peura
January 2015, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine,
Copied contents to your clipboard!